Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
Bristol Myers Squibb plans to release initial late-stage trial data on Cobenfy in Alzheimer's-related psychosis during the latter part of the year.
Bristol Myers Says New Schizophrenia Drug Off to Strong Start
Bristol Myers Squibb Co. said its new schizophrenia drug is off to a better start than similar recently launched treatments, in an early sign that its $14 billion purchase of Karuna Therapeutics is paying off.
Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports
Bristol Myers (BMY) new psychiatric drug Cobenfy is effective in treating schizophrenia without “the serious side effects’ of other older
Bristol Myers Squibb CEO describes new drug for treating schizophrenia
Bristol Myers Squibb CEO Chris Boerner described Cobenfy, a new drug to treat schizophrenia and may also help with bipolar disorder and Alzheimer’s disease.
Bristol Myers Points to New Alzheimer Drug
Bristol Myers Squibb (NYSE:BMY) believes Alzheimer’s is the largest market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars in revenue. In an interview,
KOMU
23h
FDA approves first new schizophrenia drug in more than 30 years
The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
2d
Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy
Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...
BioSpace
3d
5 Novel FDA Approvals Notched in 2024
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...
CNBC on MSN
8d
Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market
The FDA wrapped up 2024 with 50 new drug approvals, clearing a wave of long-awaited treatments. Meanwhile, Transcarent will ...
3d
on MSN
Bristol sees annual $1.5B in cost savings by end of 2025
Bristol Myers Squibb CEO Christopher Boerner said $1.5B in annual cost savings should be achieved by the end of the year.
7d
on MSN
This Unpopular Dividend Stock Is a Buy
This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...
15h
on MSN
Pick of the stats: Coventry v Bristol City
Coventry City are unbeaten across their past four home league games against Bristol City (W2 D2), since a 3-1 loss in October ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Bristol Myers Squibb
Coventry
Sheffield United F.C.
Feedback